Stock Ratings / Health Care / NVNO / options

WOK (51) SNOA (36) AMIX (34) INBS (29) ⌘ Pro Terminal →

enVVeno Medical Corporation (NVNO) Options Positioning, Max Pain & Unusual Sweeps

$6.73 -4.13% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.67

enVVeno Medical Corporation (NVNO) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $4.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NVNO Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NVNO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, enVVeno Medical Corporation (NASDAQ: NVNO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $6.73 (-4.13% 1D, market cap $4.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NVNO ranks #763 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NVNO compare to WOK and SNOA in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), NVNO carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, WOK (WORK Medical Technology Group LTD (Class A)) holds a D grade (51/100 RQD, P/E N/A, ROIC —, cap $4.9M) and SNOA (Sonoma Pharmaceuticals Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $5.7M). Among the 5-stock peer group, NVNO leads on earnings multiple (N/A) while NVNO leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NVNO?

▼

Per NVNO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001661053), enVVeno Medical Corporation generated $0 in revenue, -$19.5M in net income, and -$15.6M in free cash flow against $29.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.67 (-0.93%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NVNO)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (33/100 Composite)

🔍 WHY NVNO SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 39.8 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$8.15-5.6% Next Q

Q2 (-2Q)

Grade E$7.69-12.7% Next Q

Q3 (-1Q)

Grade E$6.71+0.3% Next Q

Current

Grade E$6.73-8.9% Hist 90D α

Trajectory: D (41) → E (33)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NVNO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NVNO currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.89) and Max Pain ($7.07) forces dealer call-delta covering toward $27.27.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NVNO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NVNO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 33%NO 67%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (NVNO)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for NVNO.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NVNO)

✓Walkthrough of NVNO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NVNO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -36.99%📐 HORIZONTAL RANGE

2026-11-02O $6.74H $7.02L $6.73C $6.73VOL 14.4K

RES: $12.81SUP: $5.61SMA50: $8.89SMA200: $10.27

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NVNO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NVNO Butterfly Map → + Track NVNO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NVNO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NVNO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NVNO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NVNO)

Health Care Rank #763 of 1016 ⚔️ WOK vs NVNO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NVNO vs. WOK, SNOA, AMIX, INBS)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, enVVeno Medical Corporation (NVNO) ranks #763 by composite RQD confidence (33/100, grade E) and #951 by equity capitalization ($4.9M). Within this direct 5-issuer industry benchmark cohort, NVNO leads on earnings valuation at N/A trailing P/E, while NVNO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. WOK currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with NVNO at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NVNO ACTIVE enVVeno Medical Corporation	E	33/100	—	—	-35.0%	-4.13%	$4.9M	Benchmark Subject
WOK WORK Medical Technology Group LTD (Class A)	D	51/100	—	—	—	-9.09%	$4.9M	/wok-vs-nvno →
SNOA Sonoma Pharmaceuticals Inc.	D-	36/100	—	38.0%	-35.0%	-8.33%	$5.7M	/snoa-vs-nvno →
AMIX Autonomix Medical Inc.	E	34/100	—	—	-35.0%	-11.27%	$4.0M	/amix-vs-nvno →
INBS Intelligent Bio Solutions Inc.	E	29/100	—	40.8%	-35.0%	-3.82%	$6.1M	/inbs-vs-nvno →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001661053

In its most recent audited fiscal period (FY2025, filed 2025-12-31), enVVeno Medical Corporation (NVNO) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$19.5M, operating cash flow of -$15.6M, and free cash flow of -$15.6M (+7.7% YoY). On the balance sheet, NVNO closed FY2025 with $29.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$19.5M	-$15.6M	-$15.6M	$29.6M	—
FY2024 (FY)	2024-12-31	$0	-$21.8M	-$16.8M	-$16.9M	$45.0M	—
FY2023 (FY)	2023-12-31	$0	-$23.5M	-$18.9M	-$18.9M	—	—

3. NVNO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NVNO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NVNO compare to WOK and SNOA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for NVNO?

Where is NVNO trading relative to its 50-day, 200-day, and 52-week technical levels?

NVNO last traded at $6.73 (-4.13% on volume of 19,185 shares), positioning the stock -24.30% below its 50-day simple moving average ($8.89) and -34.47% below its 200-day simple moving average ($10.27). Across its 52-week range of $6.52 to $25.97, NVNO sits at the 1.1% percentile with a 14-day RSI of 39.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.89 to $7.57).

NVNO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is NVNO's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for NVNO.

Direct Sub-Reports: NVNO RQD Cockpit NVNO 12M Forecast NVNO Earnings & Move NVNO Dividends & DRIP NVNO Insiders & 13F NVNO Whale Options NVNO Profit Sankey NVNO News & Why

ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

NVNO — enVVeno Medical Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:53:23Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, NVNO scores 33 out of 100, a letter grade of E, with the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine 7/20 (ROIC -35%; FCF yield 0%); Whale 13F Flow 3/20 (institutional accumulation and options positioning); Insider Conviction 5/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 8/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet 10/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5). Every pillar sits in the lower half of its range. The weakest signal is the fundamental cash engine, which the rating ties to a negative ROIC and zero free-cash-flow yield, meaning the business is not currently generating returns on capital. The institutional and insider pillars are also weak, indicating limited smart-money conviction in the data provided. The forensic balance sheet score is the strongest pillar at 10/20, reflecting an Altman Z of 2.5 and a Debt/Equity of 0.5, though a Piotroski F of 3/9 signals weak financial strength on that scale. For a prospective investor, the implication is that the rating frames NVNO as a high-risk, cash-consuming profile where the main upside would have to come from a change in the business's capacity to fund itself, not from current earnings. Valuation tradeoffs are difficult to assess because standard earnings multiples are unavailable, and the stock's low price relative to its 52-week high reflects a steep drawdown already underway.

Business

enVVeno Medical Corporation is a NASDAQ-listed issuer in the Health Care sector, operating within the Medical/Dental Instruments industry. The source profile does not describe its products, customers, or revenue model. The FY 2025 and FY 2024 filings report revenue of $0.0M in each period, indicating no reported revenue in the provided financial data. Not available in source data for detailed product or customer information.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-20.9M	$-19.5M	N/A	$-15.6M	$3.1M	N/A
FY 2024	$0.0M	$-23.8M	$-21.8M	N/A	$-16.9M	$1.8M	N/A
FY 2023	$0.0M	$-25.2M	$-23.5M	N/A	$-18.9M	N/A	N/A

Per the SEC financials, the company reported zero revenue and operating losses across all three periods, with net losses narrowing from $-23.5M in FY 2023 to $-19.5M in FY 2025. Gross, operating, and net margins are each listed as 0% in the market data, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Reported cash rose from $1.8M in FY 2024 to $3.1M in FY 2025, while free cash flow remained negative in every period. The balance-sheet posture therefore relies on cash reserves against continuing cash burn.

Recent Catalysts & News Wire Analysis

Per the recent news section, the five items carry a mix of yellow (market wire) and one red (risk watch) signal. The most significant risk item is a Kalkine Media report on a $4.4M net loss in Q3 2026 with $2.6M in cash reserves, flagged red. A Stock Titan report states that about $18.5M in cash and investments exists against a stated need for more capital, which conflicts with the $2.6M cash reserve figure in the Kalkine item and with the $3.1M FY 2025 cash figure. Other items include a StockInvest.us forecast piece, a TradingView estimates item, a Stock Titan notice of a December 10 shareholder vote on a director term through 2029, and a TradingView release of a CEO video series episode. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.

Open Questions

The cash figures conflict across sources: the FY 2025 financials show $3.1M in cash, a Kalkine item cites $2.6M in cash reserves, and a Stock Titan item cites about $18.5M in cash and investments. Which figure reflects the current balance sheet?
The Piotroski F-Score is 3/9 and the Altman Z is 2.5, but the filings do not show debt values, so the basis for the Debt/Equity of 0.5 is unclear.
What is the company's product and revenue model, given zero reported revenue across three fiscal years?
What is the expected timeline and funding source for the capital need referenced in the news items?
What drives the 52-week price decline from $25.97 to the current $7.02, and how is the December 10 shareholder vote relevant to that trajectory?

NVNO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for enVVeno Medical Corporation (NVNO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NVNO Debate Forum (3) ↓

🟡 MARKET WIRE StockInvest.us • 2h ago

Envveno Medical Stock Price Forecast. Should You Buy NVNO?

StockInvest.us report covering enVVeno Medical Corporation (NVNO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 5h ago

enVVeno Medical Corporation Estimates – NASDAQ:NVNO

TradingView report covering enVVeno Medical Corporation (NVNO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 8h ago

Stockholders will vote on a director term through 2029 at enVVeno Medical (NVNO)'s December 10 meeting.

Stock Titan report covering enVVeno Medical Corporation (NVNO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 11h ago

enVVeno Medical Releases New Episode of "WTF" Video Series Featuring CEO Rob Berman

TradingView report covering enVVeno Medical Corporation (NVNO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 14h ago

With about $18.5M in cash and investments, enVVeno (NVNO) will need more capital.

Stock Titan report covering enVVeno Medical Corporation (NVNO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Kalkine Media • 17h ago

enVVeno Medical Reports $4.4M Net Loss in Q3 2026 with $2.6M Cash Reserves

Kalkine Media report covering enVVeno Medical Corporation (NVNO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 20h ago

A study will test a valve for damaged leg veins, with its first patient expected before year's end.

Stock Titan report covering enVVeno Medical Corporation (NVNO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 23h ago

NVNO Q2 2026 Earnings: Wider-Than-Expected Loss Weighs on Pre-Revenue Device Developer - Earnings Call Transcript

https://www.dars.gov.et/ report covering enVVeno Medical Corporation (NVNO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NVNO Bull vs. Bear Conversation Board — What's Your Call at $6.73?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NVNO 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $6.18 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is NVNO (E • RQD 33/100) a Buy at $7.02?

Welcome to the NVNO (enVVeno Medical Corporation) Roar Pit. Current RQD Composite is 33/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $5.69 (-18.9%)

Spot @ $7.02

Pump the brakes on NVNO — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on NVNO, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless enVVeno Medical Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $8.92 (+27.1%)

Spot @ $7.02

NVNO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on NVNO, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $7.02 (52-wk range $6.52 - $25.97), any beat on forward guidance forces shorts and underweight funds to chase.